|
Day Two: Monday, October 1, 2007
Keynote Session 1: Bridging Diagnostics Technologies with Pharma and
Biotech
Tim Jaeger, Ph.D., M.B.A., Head of Medical and Scientific Affairs,
Diagnostics Division, F Hoffmann La Roche AG
Keynote Session 2: Creating the IT Infrastructure to Enable Adaptive
Clinical Development
The adaptive clinical development process is rapidly being employed by
pharmaceutical companies to improve the success rate of late stage
clinical programs, shorten development timelines, and permit efficient
allocation of resources. As companies move from single trial pilots to
broad implementation, the need for an underlying IT infrastructure to
support this new process is required. This presentation will discuss the
nature of this IT infrastructure and the steps required to achieve it.
Jerald S. Schindler, Dr.P.H., Vice President, Late Stage Clinical
Development Statistics, Merck & Co.
Day Three: Tuesday, October 2, 2007
Keynote Session 3: Doubling IT Innovation Spending: Laying the
Foundation for IT-Enabled Business Process, Supply Chain, and Service
Innovation in the Pharmaceutical Industry
IT leaders within the Pharmaceutical Industry are struggling to meet
two critical challenges: dramatically improve the efficiency of IT and use
that efficiency to drive business innovation. Over the last few years,
Pfizer has been putting in place the processes to dramatically reduce the
costs of IT support and maintenance, through the global rationalization of
all IT applications, information sources, and the processes which use
them. By significantly reducing the cost of IT support and maintenance
through global rationalization, Pfizer will be able to use those savings
to double the investment available for IT-enabled business process, supply
chain, and service innovation across the enterprise. The session will
focus on the key steps and lessons that Pfizer has taken to overcome these
challenges by focusing in the implementation of an IT/Business Governance
Model, IT Portfolio Management Process and a Common IT Architecture and
Services Model for supporting Pfizer’s Worldwide Business Development
activities.
Chris Asakiewicz, Ph.D., Affiliate Professor of Information Management,
Stevens Institute of Technology, Wesley J. Howe School of Technology
Management; former Vice President, Global Business Technology, Pfizer
Global Pharmaceutical Division
Keynote Session 4: Lessons Learned: Challenges Faced in Sharing
Information Across the Organization (Panel)
Marc Wine, MHA, Health Systems Analyst; Adjunct Professor, Health Services
Management and Leadership Department, The George Washington University
Donald T. Mon, Ph.D., Vice President, Practice Leadership, American
Health Information Management Association (AHIMA)
Mitchell Weisberg, Senior Principal, Hewlett Packard |
Day One: Sunday,
September 30, 2007
12:00-12:30pm Registration
12:30-4:00 Bridging Business and IT to Implement
Performance Metrics
Many Pharmaceutical and Biotechnology companies use an abundance of metrics, scorecards and dashboards to manage their business. But in many cases, these scorecards and dashboards use metrics that are not standardized across the organization – they exist as disparate metrics, compiled manually or on systems that are not integrated. This results in higher reporting costs, and makes it challenging for management to gain insight into multiple groups and divisions of the business with a consistent framework. To respond to these challenges or when developing new metrics, it is vital to engage both the business and IS. A key element to establishing standard metrics across the enterprise is implementing a well defined, consistently executed performance management methodology. This methodology must incorporate and engage the business and IT organizations in a coordinated effort to translate business performance requirements into metrics that are implemented with data and business rules. Clearly defined, standard metrics, anchored to reliable data is a critical success factor for business performance management.
This presentation will provide a case study from Amgen, a leading biotechnology company, to describe how they employed best practices for developing and implementing a common performance metric methodology across the organization. The methodology prescribes both business and technical activities to produce metrics that are aligned with strategy, leading measures of outcome, and drivers of decisions or action. The methodology provides a roadmap and repeatable, standard approach for the pharmaceutical organizations. Participants from both business and IT are encouraged to attend.
Mitchell Weisberg, Senior Principal, Hewlett Packard
Paul King, Senior Business Analyst, Amgen Corporation
*Separate Registration
Required |
